US Sen. Claire McCaskill is not done with Valeant Pharmaceuticals.
The company has been under pressure the past few weeks, first facing questions over drug pricing and then finding itself the focus of attention after short-seller Andrew Left published a report comparing it to Enron.
Valeant held an investor call Monday that was meant to address concerns over those allegations.
McCaskill, the top-ranking Democrat on the Senate’s Permanent Subcommittee on Investigations and the Senate Aging Committee, was not convinced by the call, however.
“The only thing that this morning’s investor call made clear is that Valeant’s questionable business practices extend well beyond price gouging,” McCaskillsaid in a statement.
Valeant said Monday that it would set up a committee to review business practices at Philidor, a specialty pharmacy it owns a stake in, which is at the center of fraud allegations.
Full content: Business Insider
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI